読み込み中
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
最新データ
HK$3.91
−HK$0.135 · -3.34%
日中の時刻はHKTです。市場データは遅延する場合があります。
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
日中レンジ
現在 HK$3.91
52週レンジ
現在 HK$3.91
日中の時刻はHKTです。市場データは遅延する場合があります。
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
日中レンジ
現在 HK$3.91
52週レンジ
現在 HK$3.91
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CNY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 9.11億 CNY | 3.68億 CNY | 2.25億 CNY | 1557.2万 CNY | — |
| 売上原価 | 1.79億 CNY | 7482.4万 CNY | 2827.7万 CNY | 200.5万 CNY | 1.15億 CNY |
| 粗利益 | 7.32億 CNY | 2.93億 CNY | 1.97億 CNY | 1356.7万 CNY | −1.15億 CNY |
| 研究開発 | 3.36億 CNY | 4.38億 CNY | 4.58億 CNY | 5.24億 CNY | 7.91億 CNY |
| 販売・一般管理 | 3.54億 CNY | 2.38億 CNY | 1.3億 CNY | 1.41億 CNY | 1.56億 CNY |
| 営業費用 | 6.45億 CNY | 6.84億 CNY | 1.92億 CNY | 7.18億 CNY | 10.1億 CNY |
| 受取利息 | 1200.89万 CNY | 466.7万 CNY | 670.9万 CNY | 817.3万 CNY | 414.3万 CNY |
| 支払利息 | 2855.05万 CNY | 2165万 CNY | 1467.7万 CNY | 746.7万 CNY | 269.6万 CNY |
| 減価償却費と償却費 | 9130.03万 CNY | 8391.2万 CNY | 1.03億 CNY | 9544.6万 CNY | 7718.3万 CNY |
| 営業利益 | 8743.01万 CNY | −3.91億 CNY | 479.6万 CNY | −7.04億 CNY | −10.1億 CNY |
| 純利益 | 2.55億 CNY | −4.11億 CNY | −2209.6万 CNY | −6.89億 CNY | −10.11億 CNY |
会社概要が更新されました 2026年10月5日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Core MSCI Emerging Markets ETFIEMG614.72万0.00%1621.9億 USD0.09%$83.52+1.41%
State Street SPDR Portfolio Emerging Markets ETFSPEM102.76万0.01%174.79億 USD0.07%$52.765+1.65%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX31.88万0.05%6.62億 USD0.65%$71.77+0.60%
WisdomTree China ex-State-Owned Enterprises FundCXSE30.17万0.07%4.49億 USD0.32%$35.035+1.48%
Avantis Emerging Markets Equity ETFAVEM27.52万—287.4億 USD0.33%$96.61+1.26%
iShares Core MSCI Total International Stock ETFIXUS23.38万0.00%590.95億 USD0.07%$95.9685+0.41%
Global X - Aging Population ETFAGNG18.61万0.21%8739.62万 USD0.50%$37.50+4.33%
iShares MSCI China Small-Cap ETFECNS17.46万0.28%6174.66万 USD0.59%$27.31+0.81%iShares Core MSCI Emerging Markets ETFIEMGState Street SPDR Portfolio Emerging Markets ETFSPEMState Street SPDR S&P Emerging Markets Small Cap ETFEWXWisdomTree China ex-State-Owned Enterprises FundCXSEAvantis Emerging Markets Equity ETFAVEMiShares Core MSCI Total International Stock ETFIXUSGlobal X - Aging Population ETFAGNGiShares MSCI China Small-Cap ETFECNSAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
